Monday, November 30, 2020
When confronted by antitrust regulators last year, the core thesis of Illumina and Pacific Biosciences was that PacBio could not survive as an independent company. After giving up on the merger, PacBio decided to dispute their own thesis -- and seem to be succeeding so far. As highlighted at their recent "Global Summit" meeting, they have a new CEO, new financing and a burnished product offering.
Thursday, November 19, 2020
I saw a provocative abstract in PNAS about the usage of serine codons in E.coli that triggered the "this could make an interesting student exercise" (for my prior effort, see: Exercise: A Sequence Signature for Transcription-Translation Coupling in Bacteria?). The paper is behind a paywall (though a relatively cheap one at $10) so I haven't actually read the paper, but the purposes here that isn't really a problem -- I'm not going to critique the paper, but just use the concept as a springboard.
Saturday, November 14, 2020
Back before I can remember -- as in January of this year -- I wrote a piece on the challenging situation of BioNano Genomics. I got an important detail wrong in that piece, missing some important fundraising, but in general from the point-of-view I took I thought it was a decent piece, meant to convey the challenge of a really amazing technology having its original market disappear. Some commenters took strong exception to the piece and suggested I had not-so-pure motives for writing it. They're wrong -- but at AGBT I got a chance to learn more about the company's new direction and how I hadn't been looking at things quite appropriately. I should have written it up there, but working on a response to the pandemic started taking over my life and I let time slip away. Preparing crow to be eaten also tends to be procrastinated. But here, finally, is a re-look at the company (and, I drafted this over a month ago and never finished -- the procrastination drags on...)
I was a bit nervous strolling into the BioNano Genomics booth at Marco Island. Maybe they were the ones so offended by the piece. But no, they actually invited me to come to a morning talk and to chat afterwards, and were completely professional and cordial and made it clear they understood the angle I had taken as a sincere journalistic approach. But not only did I hear the talk then, but I had gotten a preview the night before in the Twist Suite, which also illustrates a key card BioNano has: a collaboration with Alexander Hoischen
Monday, October 12, 2020
10X Genomics last week announced the purchase of ReadCoor, a company that unveiled its 3D spatial sequencing instrument back at AGBT, paying $350M to acquire the Cambridge MA company. This follows quickly on the heels of 10X purchasing Swedish in situ sequencing company CartaNA for another $41M. 10X already had the Visium spatial transcriptomics product on the market. So now 10X has three different technologies in the spatial profiling space.
Wednesday, September 30, 2020
I like to pretend in this space that I catch all the little details of the different sequencing platforms. Well, at least over time I try to do that. But ego aside, that is often a mark not made. A bit of a year ago I discovered that there's a small difference across the Illumina family that is completely separate from how clusters are generated (Bridge Amplification randomly arrayed or Exclusion Amplification in nanowells) or the wavelengths of light used in the fluorescence microscopy (now blue on the newest NextSeqs, with superresolution microscopy coming soon) or 4 color vs. 2 color vs. 1-color (well, really staged 2-color) chemistry for the reversible terminators. There's a subtle difference in how the second index is read. I'm not spilling a deep secret: it's right out in plain sight within an Illumina technical document
Monday, August 31, 2020
I've been programming 90+% in Python now for over a year and a half -- when I joined the Strain Factory I vowed to finally make the break from Perl. Partly this was disgust with so often finding libraries I wanted to be missing or broken, and partly it was recognizing that the Factory is primarily a Python shop and I would have the most impact if I worked in the lingua franca. I was first exposed to Python back at Codon Devices, but there was a strong C# faction there and I fell in love with that language, so my primary dabbling in Python was learning enough to glue the key Python code into my C# with IronPython. I strongly considered changing over at the start of Warp Drive, but gave it too weak a try and quickly started churning out Perl. I still use that language for basic level text munging, but have avoided writing nearly anything that occupies more than one screen.
Friday, July 24, 2020
I will offer here two bioinformatics programming problems which I think are interesting, useful and should be approachable by an advanced undergraduate. For a variety of reasons I've been thinking a lot of about skill levels and how to assess them. One key reason is we have two open slots in our group, so I'm plowing through CVs and engaging in the usual hiring funnel struggle -- how do you winnow CVs to phone screens and then down to interviews? We also thought we might, but now won't, bring on a one year intern. But I'm also trying to take a look at my own skill set with a critical eye. Plus I maintain a Quora addiction, and you see there people looking for ways to prove their computational biology chops.